bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: J J M A M F J
2013: D N O S A J

  Health Highlights: Feb. 13, 2014

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:

Vaccine Pellets for Mice Show Promise In Curbing Lyme Disease

An experimental vaccine to control Lyme disease in mice shows promise, according to researchers.

Controlling Lyme disease in mice would reduce its spread to people. Mice carry the bacteria that cause the condition and infect ticks who bite them. Ticks infect new mice when they feed on them, and ticks also transmit the disease to people, NBC News reported.

The vaccine created by a company called U.S. Biologic was contained in pellets eaten by mice in a wooded area of New York over five years, the researchers reported in the Journal of Infectious Diseases.

"Over a few years we saw a 75 percent reduction in the number of infected ticks," Dr. Tom Monath, a member of the board of U.S. Biologic, told NBC News. "That would almost certainly result in a reduction of human infections."

The company is seeking U.S. Department of Agriculture approval for the vaccine, which would be distributed in places where people are at risk of getting infected with Lyme disease, such as hiking paths and parks.

About 300,000 people in the United States are infected with Lyme disease every year, according to the Centers for Disease Control and Prevention.

-----

Imbruvica Approved for Treatment of Chronic Lymphocytic Leukemia: FDA

The drug Imbruvica (ibrutinib) has been approved to treat chronic lymphocytic leukemia (CLL) in patients who have undergone at least one previous type of treatment, the U.S. Food and Drug Administration said Wednesday.

This is an expanded approval for Imbruvica, which was approved in 2013 to treat mantle cell lymphoma in patients who'd had at least one previous type of treatment.

"Today's approval provides an important new treatment option for CLL patients whose cancer has progressed despite having undergone previous therapy," Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

CLL is a rare blood and bone marrow disease. About 15,680 Americans were diagnosed with CLL and 4,580 died from the disease in 2013, according to the National Cancer Institute.

Approval of the drug, made by Pharmacyclics of California, was based on a clinical trial of 48 patients with CLL who'd had previous therapy. It showed that the cancer shrank in nearly 58 percent of the patients who received Imbruvica, and that the length of the response ranged from about six to 24 months.

-----

Copyright © 2014 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=684875

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Lyme Disease
Therapeutics
Leukemia, Lymphocytic
Neoplasms
Leukemia
Research Personnel
Bone Marrow
Infection
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact